While there are several commonly-cited reasons for the present pre-eminence of the Cambridge-Boston. USA, biotech cluster, it's clear that the hub is greater than the sum of its parts.
According to one estimate, the main hub in Cambridge contains firms that have attracted over $14 billion in investments from venture-capitalists.
And while the area plays host to an array of biomedical firms, both very small and very large, a cornucopia of suppliers, contract research organizations, investors, lawyers and others have also been built up to support them.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze